Author Archives: Marisa Wexler MS

Experts Issue Guidance for Care of Scleroderma Patients During COVID-19

With the World Scleroderma Foundation (WSF)’s support, experts worldwide answered questions in the form of  recommendations for scleroderma patients amid the COVID-19 outbreak, including the importance of maintaining current medications and discussing any changes with their doctors. Their guidelines, “Systemic sclerosis and the COVID-19 pandemic:…

Tracleer Seen to Ease Skin Symptoms in Small Scleroderma Study

One year of treatment with Tracleer (bosentan) significantly reduces the severity of patient-reported skin symptoms in people with scleroderma, a new study suggests. Yet, these benefits are diminished among those with more severe complications before treatment. The study, “A patient-centered approach to the burden…

FDA Paves Way for Phase 2 Testing of EHP-101 for Scleroderma

The U.S. Food and Drug Administration (FDA) has cleared an application from Emerald Health Pharmaceuticals that paves the way to begin a Phase 2 clinical trial testing EHP-101 in people with scleroderma. EHP-101 is an oral therapy based on cannabidiol (CBD), one of the main components of cannabis and…